	US 12,343,359 B2
	Inhibitory interneuron treatment methods, uses and compositions for diabetes
Zaman Mirzadeh, Phoenix, AZ (US)
Assigned to DIGNITY HEALTH, San Francisco, CA (US)
Appl. No. 17/613,391
Filed by DIGNITY HEALTH, San Francisco, CA (US)
PCT Filed May 18, 2020, PCT No. PCT/US2020/033368 § 371(c)(1), (2) Date Nov. 22, 2021, PCT Pub. No. WO2020/236696, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/851,752, filed on May 23, 2019.
Prior Publication US 2022/0241343 A1, Aug. 4, 2022
Int. Cl. A61K 35/39 (2015.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 35/30 (2015.01); A61P 3/10 (2006.01)

CPC A61K 35/30 (2013.01) [A61K 9/0085 (2013.01); A61K 9/08 (2013.01); A61P 3/10 (2018.01)]

10 Claims

1. A method for the treatment of a mammal having pre-diabetes or diabetes, comprising:

administering an effective amount of mammalian MGE (medial ganglionic eminence) precursor cells to one or more of an arcuate nucleus of the hypothalamus region of the brain, the mediobasal hypothalamus region of the brain, and the ventromedial hypothalamus region of the brain, wherein the mammalian MGE precursor cells form interneurons that functionally integrate with endogenous neurons such that an improvement in the symptoms of prediabetes or diabetes in the treated mammal is achieved.